4.8 Article

TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis

Journal

CANCER RESEARCH
Volume 77, Issue 12, Pages 3181-3193

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-16-2797

Keywords

-

Categories

Funding

  1. NIH [F31CA189588, P50CA103175, U54CA141868, HL107361, R01CA166348, U01CA183031]
  2. Uniting Against Lung Cancer Young Investigator Award
  3. Motta and Nesbitt Families
  4. DoD [W81XWH-11-1-0272]
  5. Kimmel Translational Science Award [SKF-13-021]
  6. ACS Scholar award [122688-RSG-12-196-01-TBG]
  7. American Lung Association [LCD-339465]
  8. Movember-PCF
  9. Pacific Northwest CaP SPORE [P50CA97186]
  10. Richard M. Lucas Foundation
  11. [NIH-T32CA121937]

Ask authors/readers for more resources

TWIST1 is a transcription factor critical for development that can promote prostate cancer metastasis. During embryonic development, TWIST1 and HOXA9 are coexpressed in mouse prostate and then silenced postnatally. Here we report that TWIST1 and HOXA9 coexpression are reactivated in mouse and human primary prostate tumors and are further enriched in human metastases, correlating with survival. TWIST1 formed a complex with WDR5 and the lncRNA Hottip/HOTTIP, members of the MLL/COMPASS-like H3K4 methylases, which regulate chromatin in the Hox/HOX cluster during development. TWIST1 overexpression led to coenrichment of TWIST1 and WDR5 as well as increased H3K4me3 chromatin at the Hoxa9/HOXA9 promoter, which was dependent on WDR5. Expression of WDR5 and Hottip/HOTTIP was also required for TWIST1-induced upregulation of HOXA9 and aggressive cellular phenotypes such as invasion and migration. Pharmacologic inhibition of HOXA9 prevented TWIST1-induced aggressive prostate cancer cellular phenotypes in vitro and metastasis in vivo. This study demonstrates a novel mechanism by which TWIST1 regulates chromatin and gene expression by cooperating with the COMPASS-like complex to increase H3K4 trimethylation at target gene promoters. Our findings highlight a TWIST1-HOXA9 embryonic prostate developmental program that is reactivated during prostate cancer metastasis and is therapeutically targetable. (C)2017 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available